Fresh Tracks Therapeutics, Inc. Common Stock
FRTX
FRTX was delisted on the 18th of December, 2023.
23 hedge funds and large institutions have $6.87M invested in Fresh Tracks Therapeutics, Inc. Common Stock in 2017 Q3 according to their latest regulatory filings, with 1 funds opening new positions, 7 increasing their positions, 6 reducing their positions, and 5 closing their positions.
17% more repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 6
5% less capital invested
Capital invested by funds: $7.2M → $6.87M (-$333K)
18% less funds holding
Funds holding: 28 → 23 (-5)
80% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 5
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AI
Ariel Investments
Chicago,
Illinois
|
+$493K |
| 2 |
Renaissance Technologies
New York
|
+$250K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$170K |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$151K |
| 5 |
New York State Common Retirement Fund
Albany,
New York
|
+$62.5K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$520K |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$67K |
| 3 |
Goldman Sachs
New York
|
-$35K |
| 4 |
AIM
Acrospire Investment Management
Chicago,
Illinois
|
-$13K |
| 5 |
JP Morgan Chase
New York
|
-$12K |
FRTX Hedge Fund Activity: Q3 2017 in Review
23 of the 4,012 institutional investors tracked by Wall St. Rank reported a position in Fresh Tracks Therapeutics, Inc. Common Stock (FRTX) for Q3 2017, worth a combined $6.87M — down 4.6% from $7.2M a quarter earlier.
Sellers outnumbered buyers: 5 funds closed out of FRTX and 1 opened new positions — a net loss of 4 holders — while 6 trimmed existing stakes and 7 added.
The largest buyer was Ariel Investments, adding an estimated $493K. The largest seller was Fidelity Investments, cutting an estimated $520K.
- 23 institutional investors held Fresh Tracks Therapeutics, Inc. Common Stock (FRTX) as of Q3 2017, down from 28 in Q2 2017.
- Funds reported $6.87M of Fresh Tracks Therapeutics, Inc. Common Stock stock for Q3 2017, down 4.6% quarter-over-quarter.
- 1 fund opened new Fresh Tracks Therapeutics, Inc. Common Stock positions in Q3 2017 and 5 closed out, a net change of -4 holders.
- The largest Fresh Tracks Therapeutics, Inc. Common Stock buyer in Q3 2017 was Ariel Investments, an estimated $493K added.
- The largest Fresh Tracks Therapeutics, Inc. Common Stock seller in Q3 2017 was Fidelity Investments, an estimated $520K sold.
Based on aggregated 13F filings for Q3 2017.